NCT05370430View on ClinicalTrials.gov

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

July 13, 2027

Study Completion Date

June 13, 2028

Conditions
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Interventions
BIOLOGICAL

BAFFR-CAR T cells

First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL

Trial Locations (5)

28204

RECRUITING

Atrium Health Levine Cancer Institute - Morehead, Charlotte

55455

RECRUITING

University of Minnesota, Minneapolis

91010

RECRUITING

City of Hope Medical Center, Duarte

94305

RECRUITING

Stanford University, Stanford

98104

RECRUITING

Providence Swedish Cancer Institute, Seattle

Sponsors
All Listed Sponsors
collaborator

City of Hope Medical Center

OTHER

lead

PeproMene Bio, Inc.

INDUSTRY

NCT05370430 - BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL | Biotech Hunter | Biotech Hunter